跳至主要内容
临床试验/EUCTR2012-002422-78-GB
EUCTR2012-002422-78-GB进行中(未招募)1 期

Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial. - Effects of Liraglutide in Young adults with Type 2 DIAbetes (LYDIA)

niversity of Leicester0 个研究点目标入组 90 人开始时间: 2013年7月23日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Capacity to provide informed consent before any trial-related activities •Aged 18 – 50 years inclusive •Established T2DM (>12 months) •BMI = 30 kg/m2 (=27 kg/m2 for South Asians or other BME populations) •On mono or combination oral OAD therapy (sulphonylurea and/or metformin) for = 3 months •No prescribed thiazolidinediones within the last 3 months •An HbA1c value of >= 6.5% and <= 10%
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 90
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Absolute contraindications to MRI •Type 1 diabetes (identified through C-peptide analysis) •Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods •Suffer from terminal illness •Have impaired renal function (eGFR < 30 ml/min/1.73m2) ) •Impaired liver function (ALAT=2.5 times upper limit of normal) •Known to be Hepatitis B antigen or Hepatitis C antibody positive •Clinically significant active cardiovascular disease including history of myocardial infarction within the past 6 months and/or heart failure (NYHA class III and IV) at the discretion of the investigator •Recurrent major hypoglycaemia as judged by the investigator •Known or suspected allergy to the trial products •Receipt of any investigational drug within four weeks prior to this trial •Have severe and enduring mental health problems •Are not primarily responsible for their own care •Are receiving insulin therapy •Have taken a thiazolidinedione within the last 3 months •Any contraindication to Sitagliptin or Liraglutide •Have severe irritable bowel disorder •Have pancreatitis or a previous history of pancreatitis

研究者

发起方
niversity of Leicester

相似试验

进行中(未招募)
1 期
An MR-scan study of Liraglutide on cardiac function and cardiac blood flow in patients with type 2 diabetes and impaired filling of the heart.Type 2 diabetes mellitus and diastolic heart faliureMedDRA version: 18.0Level: LLTClassification code 10069211Term: Diastolic heart failureSystem Organ Class: 100000004849MedDRA version: 18.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861
EUCTR2015-000410-22-DKThe Cardiovascular MR Group, Dept. 2011, Rigshospitalet40
进行中(未招募)
不适用
Effect of Liraglutide on metabolism and function of the left ventricle in patients with type 2 diabetes and heart problems: study with RMN investigations
EUCTR2011-001408-37-ITFONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
进行中(未招募)
1 期
The Effect the Study Drug has on the Heart in Patients with Type 2 Diabetes.Cardiovascular events in patients with Type 2 diabetesMedDRA version: 14.1Level: HLTClassification code 10012654Term: Diabetic complications cardiovascularSystem Organ Class: 10014698 - Endocrine disorders
EUCTR2010-023799-21-LVEli Lilly and Company9,600
进行中(未招募)
1 期
The Effect of Dulaglutide on Major Cardiovascular Events inPatients with Type 2 Diabetes: Researching CardiovascularEvents with a Weekly INcretin in Diabetes (REWIND) - REWINDCardiovascular events in patients with Type 2 diabetesMedDRA version: 20.0Level: HLTClassification code 10012654Term: Diabetic complications cardiovascularSystem Organ Class: 100000004860
EUCTR2010-023799-21-HUEli Lilly and Company9,901
进行中(未招募)
1 期
The Effect the Study Drug has on the Heart in Patients with Type 2 Diabetes.
EUCTR2010-023799-21-SEEli Lilly & Company9,901